Product Name:
Fyn-ANT
Product Number:
ab-nk064-3
Target Full Name: Fyn proto-oncogene-encoded protein-tyrosine kinase
Target Alias: Fyn; Fyn oncogene related to SRC, FGR, YES; Kinase Fyn; MGC45350; P59-Fyn; P59-Fyn; SLK; SYN; hCG_34806; RP1-66H14.1-003; CCDS5094.1; ENSG00000010810
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK065-2
Antibody Target Type: Pan-specific
Protein UniProt: P06241
Protein SigNET: P06241
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Fyn sequence peptide Cat. No.: PE-01BCZ99
Antibody Immunogen Sequence: CKDKEATKLTEERDGSLNQS
Antibody Immunogen Description: Corresponds to amino acid residues C6 to S25; Near N-terminus
Production Method: Corresponds to amino acid residues C6 to S25; Near N-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-60 kDa.
Related Product 1: Fyn-ANT blocking peptide
Related Product 2: Fyn-pY213+pY214 phosphosite-specific antibody (Cat. No.: AB-PK644)
Related Product 3: Fyn-pY531 phosphosite-specific antibody (Cat. No.: AB-PK645)
Related Product 4: FynSubtide - Fyn protein kinase substrate peptide
Scientific Background: Fyn is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that mediates cell growth, survival, and adhesion. This kinase is highly expressed and widely distributed in most tested human tissues. Fyn is inhibited by phosphorylation at Y531. Fyn has been shown to phosphorylate Dab1, an intracellular adaptor protein that interacts with amyloid precursor protein (APP) and apoE receptor 2 (apoEr2). The interaction of Fyn and Dab1 regulates the phosphorylation, trafficking, and processing of APP and apoEr2. Fyn can interact with Fyn-binding protein and the p85 subunit of PI3K. It has been shown to be part of a protein complex involving DCC and FAK, which is downstream of Netrin-1, a pathway important in promoting both axonal outgrowth and axonal guidance in path finding. Fyn may be an oncoprotein (OP) based on its similarity to other Src family kinases that are known oncoproteins. Fyn expression has been shown to be significantly increased in Chronic Myelogenous Leukemia (CML). Knockdown of Fyn with shRNA slows leukemia cell growth, inhibits clonogenicity, and leads to increased sensitivity to imatinib. Fyn has also been linked with the development of lung squamous cell carcinomas (LSCC), melanomas (metastatic) and epilepsy. The active form of the protein kinase normally acts to promote tumour cell proliferation. Fyn has been linked with estrogen-receptor negative breast cancer, which is related to breast and colon cancer, and it may affect breast, lymph node, or lung tissues. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.
